A detailed history of Gsa Capital Partners LLP transactions in Immunic, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 32,766 shares of IMUX stock, worth $35,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,766
Previous 116,765 71.94%
Holding current value
$35,387
Previous $130,000 58.46%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$1.08 - $1.95 $90,718 - $163,798
-83,999 Reduced 71.94%
32,766 $54,000
Q2 2024

Aug 15, 2024

BUY
$0.98 - $1.44 $114,429 - $168,141
116,765 New
116,765 $130,000
Q4 2022

Feb 13, 2023

BUY
$1.13 - $10.8 $55,896 - $534,232
49,466 Added 166.44%
79,186 $111,000
Q3 2022

Nov 14, 2022

BUY
$3.0 - $5.49 $89,160 - $163,162
29,720 New
29,720 $94,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $33M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.